What does VESALE PHARMACEUTICA do?

VESALE PHARMACEUTICA is a wholesaler in Gembloux. Public Limited, started on 16 March 1994, 2 establishments.

What is the address of VESALE PHARMACEUTICA?

The registered office of VESALE PHARMACEUTICA is located at Rue Jean Sonet,Isnes 29, 5032 Gembloux.

Is VESALE PHARMACEUTICA still active?

Yes. According to the CBE (29 October 2026) VESALE PHARMACEUTICA is active, legal situation “Normale toestand”, started on 16 March 1994.

Is VESALE PHARMACEUTICA registered on Peppol?

Yes, VESALE PHARMACEUTICA is registered on the Peppol network with ID 0208:0452282591.

What is the enterprise number of VESALE PHARMACEUTICA?

The enterprise number of VESALE PHARMACEUTICA is BE0452282591.

When was VESALE PHARMACEUTICA founded?

VESALE PHARMACEUTICA was founded on 16 March 1994.

Who are the directors of VESALE PHARMACEUTICA?

According to the 2025 annual accounts, the directors of VESALE PHARMACEUTICA are: Nathalie Géruzet, Aquitania SA, MD Consult SA, Rode Ventures SRL, Vesale Pharma International SA, Jehan Lienart van Lidth de Jeude.

Is VESALE PHARMACEUTICA a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 16 March 1994; 5 annual accounts filed, latest fiscal year 2025; 6 directors known from the annual account; 2 establishments in the CBE.

How much profit did VESALE PHARMACEUTICA make in 2025?

VESALE PHARMACEUTICA recorded a loss after taxes of € 362,888 in financial year 2025.

What is the revenue of VESALE PHARMACEUTICA?

As a small company, VESALE PHARMACEUTICA is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 2,195,184.

How much does an employee at VESALE PHARMACEUTICA earn?

The average wage cost per full-time employee at VESALE PHARMACEUTICA was € 101,000 in 2025: staff costs of € 282,756 for 2.8 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does VESALE PHARMACEUTICA have?

According to the 2025 annual accounts, VESALE PHARMACEUTICA has 2.8 full-time equivalents (FTE).

VESALE PHARMACEUTICA (Public Limited) - Gembloux

Dossier VESALE PHARMACEUTICA, printed on 29 October 2026 from databakkes.be/en/0452282591/vesale-pharmaceutica. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Shrinking team NBB

FTE fell two years in a row, from 7 to 2.8.
Figures corrected NBB

Corrected annual account filed for 2023.

Financials

Financial year 2025

VESALE PHARMACEUTICA from Gembloux, company number BE0452282591, closed financial year 2025 with a result of € -362,888 after tax. For that financial year VESALE PHARMACEUTICA recorded a gross margin of € 2.2 million and equity of € 3.1 million. Compared with financial year 2024, the result moved from € 242,636 to € -362,888. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 29, 2026.

What it is worth Healthy

€ 3.1 million

▼ 10% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Loss Caution

€ -362,888

▼ still € 242,636 profit in 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 1.5 million

▲ € 1.4 million vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Caution

Loss, nothing to pay out

Reserves fell to € 804,110.

People and assets in 2025

Full-time equivalents

2.8

▼ 3.2 vs 2024

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 282,756

▼ 38% vs 2024

€ 101,000 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 9,383

▼ 53% vs 2024

Of which on lease € 0.

Debts at end 2025

Bank debt

€ 88,163

▼ 33% vs 2024

Loans from banks and other lenders, long and short.

Owed to suppliers

€ 644,478

▲ 9% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Wages and social charges

€ 32,837

▼ 12% vs 2024

Wages, holiday pay and social contributions still to pay. No outstanding taxes.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 1,068,789 Gross margin 2022: € 1,068,789 First fiscal year in the series	€ 1,067,709 Gross margin 2023: € 1,067,709 Unchanged (€ 1,068,789) Unfavourable step	€ 1,050,131 Gross margin 2024: € 1,050,131 ▼ 2% vs 2023 (€ 1,067,709) Unfavourable step	€ 2,195,184 Gross margin 2025: € 2,195,184 ▲ 109% vs 2024 (€ 1,050,131) Favourable step	▲ 109%
Profit after taxes	€ 340,451 Profit after taxes 2022: € 340,451 First fiscal year in the series	€ 206,076 Profit after taxes 2023: € 206,076 ▼ 39% vs 2022 (€ 340,451) Unfavourable step	€ 242,636 Profit after taxes 2024: € 242,636 ▲ 18% vs 2023 (€ 206,076) Favourable step	€ -362,888 Profit after taxes 2025: € -362,888 ▼ € 605,524 vs 2024 (€ 242,636) Unfavourable step	▼ € 605,524
Equity	€ 3,018,286 Equity 2022: € 3,018,286 First fiscal year in the series	€ 3,224,362 Equity 2023: € 3,224,362 ▲ 7% vs 2022 (€ 3,018,286) Favourable step	€ 3,466,998 Equity 2024: € 3,466,998 ▲ 8% vs 2023 (€ 3,224,362) Favourable step	€ 3,104,110 Equity 2025: € 3,104,110 ▼ 10% vs 2024 (€ 3,466,998) Unfavourable step	▼ 10%
Total debts	€ 2,444,828 Total debts 2022: € 2,444,828 First fiscal year in the series	€ 1,721,077 Total debts 2023: € 1,721,077 ▼ 30% vs 2022 (€ 2,444,828) Favourable step	€ 1,056,700 Total debts 2024: € 1,056,700 ▼ 39% vs 2023 (€ 1,721,077) Favourable step	€ 920,824 Total debts 2025: € 920,824 ▼ 13% vs 2024 (€ 1,056,700) Favourable step	▼ 13%
Cash	€ 109,472 Cash 2022: € 109,472 First fiscal year in the series	€ 98,388 Cash 2023: € 98,388 ▼ 10% vs 2022 (€ 109,472) Unfavourable step	€ 120,853 Cash 2024: € 120,853 ▲ 23% vs 2023 (€ 98,388) Favourable step	€ 1,506,679 Cash 2025: € 1,506,679 ▲ € 1.4 million vs 2024 (€ 120,853) Favourable step	▲ € 1.4 million
Retained profit	€ 718,286 Retained profit 2022: € 718,286 First fiscal year in the series	€ 924,362 Retained profit 2023: € 924,362 ▲ 29% vs 2022 (€ 718,286) Favourable step	€ 1,166,998 Retained profit 2024: € 1,166,998 ▲ 26% vs 2023 (€ 924,362) Favourable step	€ 804,110 Retained profit 2025: € 804,110 ▼ 31% vs 2024 (€ 1,166,998) Unfavourable step	▼ 31%
Bank debt	€ 654,193 Bank debt 2022: € 654,193 First fiscal year in the series	€ 132,244 Bank debt 2023: € 132,244 ▼ 80% vs 2022 (€ 654,193) Favourable step	€ 132,244 Bank debt 2024: € 132,244 Unchanged (€ 132,244) Unchanged	€ 88,163 Bank debt 2025: € 88,163 ▼ 33% vs 2024 (€ 132,244) Favourable step	▼ 33%
Balance sheet total	€ 5,463,114 Balance sheet total 2022: € 5,463,114 First fiscal year in the series	€ 4,945,439 Balance sheet total 2023: € 4,945,439 ▼ 9% vs 2022 (€ 5,463,114) Unchanged	€ 4,523,698 Balance sheet total 2024: € 4,523,698 ▼ 9% vs 2023 (€ 4,945,439) Unchanged	€ 4,024,934 Balance sheet total 2025: € 4,024,934 ▼ 11% vs 2024 (€ 4,523,698) Unchanged	▼ 11%
Employees (FTE)	6.1 Employees (FTE) 2022: 6.1 First fiscal year in the series	7 Employees (FTE) 2023: 7 ▲ 0.9 vs 2022 (6.1) Unchanged	6 Employees (FTE) 2024: 6 ▼ 1 vs 2023 (7) Unchanged	2.8 Employees (FTE) 2025: 2.8 ▼ 3.2 vs 2024 (6) Unchanged	▼ 3.2

Key figures of VESALE PHARMACEUTICA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to VESALE PHARMACEUTICA?

What happened at VESALE PHARMACEUTICA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

2031 Aquitania SA stepped down as director. NBB
2031 MD Consult SA stepped down as director. NBB
Jul 29, 2026 New annual accounts for financial year 2025: loss of € 362,888 (▼ € 605,524 vs 2024). Source: NBB ↗
2025 Jehan Lienart van Lidth de Jeude stepped down as director. NBB
2025 Nathalie Géruzet stepped down as director. NBB
2025 Aquitania SA became a director. NBB
2025 MD Consult SA became a director. NBB
2025 Rode Ventures SRL stepped down as director. NBB

In short

From € 340,451 profit in 2022 to € 362,888 loss in 2025.

Paid € 36,127 in corporate taxes since 2022.

Best year ever: 2022, with € 340,451 profit.

On average € 784,000 of value added per employee in 2025.

Original PDFs at the National Bank ↗

Management

Ceres Pharma 100%

The stake of Ceres Pharma comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

VESALE PHARMACEUTICA

The shares are held by Ceres Pharma (100%).

Directors

According to the 2025 annual accounts

Nathalie Géruzet

Director

since 2020 · until 2025

Aquitania SA

Director · represented by Anja Imschoot

Also active at: Ceres Pharmaceuticals, b+pharma Belgium, DGPharma, Labophar, 2PHARMA HOLDING, MD Pharma, GLOBIFER INTL, CREDOPHAR +1 more

since 2025 · until 2031

MD Consult SA

Director · represented by Mario Debel

Also active at: Ceres Pharmaceuticals, 2PHARMA HOLDING, MD Pharma, Azur Medical, AUGMENTED ANATOMY, GLOBIFER INTL, CREDOPHAR, 2PHARMA

since 2025 · until 2031

Rode Ventures SRL

Director · represented by Pierre Iweins d'Eechoutte

Also active at: BROUWERIJ-HANDELSMAATSCHAPPIJ, ARTIFREEZE, OP FOODS

since 2019 · until 2025

Vesale Pharma International SA

Managing director · represented by Jehan Lienart van Lidth de Jeude

since 2019 · until 2025

Jehan Lienart van Lidth de Jeude

Director

since 2025 · until 2025

Shareholders

Ceres Pharma

100%

Participations

No participations in other companies reported.

Establishments

Establishment units

Physical locations of this company

Registered office

Rue Jean Sonet,Isnes 29

5032 Gembloux

2.066.742.772

Rue Louis Allaert,Noville 9

5310 Eghezée

Active since 12 October 1999

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0452.282.591

VAT number

BE 0452.282.591

Registered office

Rue Jean Sonet,Isnes 29, 5032 Gembloux

Names & denominations

VESALE PHARMACEUTICA · VESALE PHARMA

Enterprise type

Rechtspersoon

Legal form

Public limited company

Legal situation

Normale toestand

Start date

16 March 1994

Peppol

Active · Active since 11 Dec 2025

Activities · NACE

Groothandel in farmaceutische en medische artikelen

Groothandel in farmaceutische producten

Groothandel in parfumerieën en cosmetica

View on CBE Public ↗ Annual accounts (NBB) ↗